WAVE LIFE SCIENCES LTD. Increase (Decrease) in Deferred Revenue
WAVE LIFE SCIENCES LTD. (WVE) reported Increase (Decrease) in Deferred Revenue of -$1.42 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2018-05-09
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2018-03-31 was -$1.42M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2017-12-31 was -$676.00K.
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2017-09-30 was -$676.00K, a 132.05% decline year-over-year.
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for the quarter ending 2017-06-30 was -$969.00K.
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for fiscal 2017 was -$2.70M, a 124.55% decline from fiscal 2016.
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for fiscal 2016 was $11.02M.
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for fiscal 2015 was -$152.00K, a 200.00% decline from fiscal 2014.
- WAVE LIFE SCIENCES LTD. increase (decrease) in deferred revenue for fiscal 2014 was $152.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 3 month as first filed | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | -$1.42M 10-Q · filed 2018-05-09 | -$2.10M derived: sum of 2 quarters · filed 2018-05-09 | -$2.77M derived: sum of 3 quarters · filed 2018-05-09 | -$3.74M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | -$676.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$1.35M derived: sum of 2 quarters · filed 2018-03-12 | -$2.32M derived: sum of 3 quarters · filed 2018-03-12 | -$2.70M 10-K · filed 2018-03-12 | |
| 2017-09-30 | -$676.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$1.65M derived: sum of 2 quarters · filed 2017-11-09 | -$2.03M 10-Q · filed 2017-11-09 | -$2.71M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-06-30 | -$969.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$1.35M 10-Q · filed 2017-08-09 | -$2.03M derived: sum of 3 quarters · filed 2018-05-09 | $80.00K derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-03-31 | -$383.00K 10-Q · filed 2018-05-09 | -$676.00K 10-Q · filed 2017-05-10 | -$1.06M derived: sum of 2 quarters · filed 2018-05-09 | $1.05M derived: sum of 3 quarters · filed 2018-05-09 | |
| 2016-12-31 | -$677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.43M derived: sum of 2 quarters · filed 2018-03-12 | $11.02M 10-K · filed 2018-03-12 | ||
| 2016-09-30 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $11.69M 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | $9.58M 10-Q · filed 2017-08-09 | ||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | -$126.00K derived: sum of 3 quarters · filed 2018-03-12 | -$152.00K 10-K · filed 2018-03-12 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$126.00K derived: sum of 2 quarters · filed 2016-11-09 | -$152.00K 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$152.00K 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | -$26.00K 10-Q · filed 2016-05-16 | ||||
| 2014-12-31 | $152.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |